Business
To Help Prepare for the COVID-19 Patient Surge Cumberland Pharmaceuticals Expands Availability of Vaprisol® to Treat Hyponatremia in Critical Care Units
- Vaprisol® safely and effectively addresses hyponatremia in the first 24 hours - Over 30% of patients admitted to the ICU have hyponatremia and another 18%
About this update from Cumberland Pharmaceuticals Inc.
[{"type":"text","content":"- Vaprisol® safely and effectively addresses hyponatremia in the first 24 hours\n - Over 30% of patients admitted to the ICU have hyponatremia and another 18% develop it while in the ICU\n - Hyponatremia has been found to increase length of stay, mechanical ventilator days and mortality\n\n\nNASHVILLE, Tenn., April 7, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) a specialty pharmaceutical company, today announced an initiative to increase availability of Vaprisol® (conivaptan hydrochloride) injection for treating hyponatremia, associated with critical care patients during the COVID-19 pandemic. Vaprisol is an FDA approved treatment for hyponatremia, a potentially life-threatening condition that can often afflict patients in the Intensive Care Unit (\"ICU\").\n\n \n \n \n \n \n \n\n \nCumberland's initiative includes special supply and financial arrangements, including favorable pricing and payment terms, for hospitals and clinics to help ensure timely access to Vaprisol during this healthcare crisis. For more information regarding this special access, contact Jim Herman, Cumberland's Senior Vice President National Accounts at [email protected].\n\"It is our hope that this enhanced access to Vaprisol will help lead to shorter ICU stays and thereby free-up potentially life-saving ICU beds that could become in short supply during the COVID-19 pandemic,\" said A.J. Kazimi, Chief Executive Officer of Cumberland Pharmaceuticals Inc. \nHyponatremia frequently occurs when the concentration of sodium in a patient's blood is abnormally low, which can lead to neurologic dysfunction, decreased mental function and cerebral edema, among other complications. The condition is particularly prevalent among ICU patients. On average, over 30 percent of patients admitted to an ICU have hyponatremia1 and another 18 percent develop the condition during their ICU stay2. Several studies have shown that patients with hyponatremia spend a longer time in the ICU, spend more time on mechanical ventilators and have increased mortality while in the ICU3. Vaprisol can help address hyponatremia in the first 24 hours4. \nFor more information on Vaprisol, including important dosing and safety instructions, please see the product website and package insert at www.vaprisol.com.\nReferences:\nPadni R, Panda BN, Jagati S, et al. Hypo...